CN108112997A - A kind of health-care food composition - Google Patents
A kind of health-care food composition Download PDFInfo
- Publication number
- CN108112997A CN108112997A CN201711365869.6A CN201711365869A CN108112997A CN 108112997 A CN108112997 A CN 108112997A CN 201711365869 A CN201711365869 A CN 201711365869A CN 108112997 A CN108112997 A CN 108112997A
- Authority
- CN
- China
- Prior art keywords
- parts
- health
- collagen
- care food
- food composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 235000013305 food Nutrition 0.000 title claims abstract description 22
- 102000008186 Collagen Human genes 0.000 claims abstract description 53
- 108010035532 Collagen Proteins 0.000 claims abstract description 53
- 229920001436 collagen Polymers 0.000 claims abstract description 53
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 32
- 230000007062 hydrolysis Effects 0.000 claims abstract description 24
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 24
- 210000000845 cartilage Anatomy 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 claims abstract description 4
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 5
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 5
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 5
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 235000010204 pine bark Nutrition 0.000 claims description 2
- 229920002414 procyanidin Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229960004756 ethanol Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 229940088598 enzyme Drugs 0.000 abstract description 10
- 210000001188 articular cartilage Anatomy 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 229920002674 hyaluronan Polymers 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 206010007710 Cartilage injury Diseases 0.000 abstract description 5
- 210000003321 cartilage cell Anatomy 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 102000016942 Elastin Human genes 0.000 abstract description 3
- 108010014258 Elastin Proteins 0.000 abstract description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 3
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 3
- 239000000084 colloidal system Substances 0.000 abstract description 3
- 229920002549 elastin Polymers 0.000 abstract description 3
- 229960002773 hyaluronidase Drugs 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 210000003097 mucus Anatomy 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 2
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 2
- 230000001925 catabolic effect Effects 0.000 abstract description 2
- 230000003412 degenerative effect Effects 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000011122 softwood Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001480581 Marasmius Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001145025 Saussurea involucrata Species 0.000 description 1
- 241000120020 Tela Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides a kind of for preventing and treating the health-care food composition of articular cartilage damage, the health-care food composition is compounded bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark in specific proportions, wherein, bone collagen can increase the colloid and mucus in joint, accelerate the reparation and existence of cartilaginous tissue and joint fluid；Hydrolysis typeⅡ Collagen helps against chondroprotein catabolic enzyme, recombinates destroyed cartilage cell；Sulforaphen in Caulis et Folium Brassicae capitatae causes the effect of a variety of enzymes of the degenerative joint of osteoarthritis by prevention, and process is damaged so as to slow down cartilage；The procyanidine enriched contained by Pine Bark has apparent inhibitory action to clostridiopetidase A, pancreatopeptidase E and hyaluronidase etc., so as to reduce destruction of these enzymes to substances such as collagen, elastin laminin, hyaluronic acids.
Description
Technical field
The present invention relates to a kind of health-care food compositions, and in particular to one kind has prevention and treatment articular cartilage damage work(
The health-care food composition of energy, the health-care food composition are suitble to professional athlete, fitness enthusiasts, bodybuilders, happiness
Love movement personage, women, old man and all outdoor body-building groups.
Background technology
With advancing age, human body is by growth period, maturity period, and then into the decline phase, the form of human body, structure and
Function is constantly occurring variation, this is the inexorable law of metabolism.For everyone, osteoarthritis can not almost be kept away
Exempt from, in diseased joint, the cartilage for playing the gentle punching of covering to bone end is progressively degenerated, and will be made mutual between bone
Friction increase.The quantity of middle-aged and elderly people soma is on a declining curve with age growth, and cell quantity is reduced year by year, outstanding behaviours
It is reduced for the weight of musculature, phenomena such as muscular atrophy occurs.The variation of middle-aged and elderly people's body composition is also manifested by bone,
Bone tissue minerals and bone matrix are reduced, and bone density reduces, and bone strength declines, and osteoporosis phenomenon and Bones and joints easily occurs
It is scorching.It is rarely found in osteoarthritis in fact, although inflammation is one of many arthritic features.Because osteoarthritis
Most important feature is the pain rather than inflammation in joint.
Osteoarthritis is a kind of arthralgia caused by Articular cartilage degeneration and joint function disturbance (including closing
Section deformity) person in middle and old age's common disease.Osteoarthritis comes from the lesion of cartilage, the elastic tela gelatinosa of cartilage, that is, bone end,
About containing 65%~80% moisture, mainly have the function of following two：Reduce the friction between bone；Mitigate daily life
In repeated trauma to bone.
For any crowd, the prevalence proportions of osteoarthritis can reach 33%~66%.This data is accurate not to the utmost, but
It equitably says, in Human Osteoarthritis, the people less than 45 years old accounts for 2%, and the people of 45~64 years old accounts for 30%, and the people more than 65 years old accounts for
63%~85%.Real data actually may also want higher, because symptom not yet occur in many people for having osteoarthritis.It is strong
The elemental of health cartilage：Collagen, proteoglycan, cartilage cell and water, their cooperating syringes ensure that physical activity can be suitable
It freely carries out, does not generate feeling of pain.Therefore, some ingredients for recovering cartilage matrix normal equilibrium are taken, in the pre- of osteoarthritis
It is of great significance in anti-and pathogenic process.
101961110 A of patent document CN disclose a kind of with nutrition cartilaginous tissue, the function of anti-arthritis effect
The preparation method of food.Be with mountain Zhu's extract, CNNS's Marasmius extract, D-Glucosamine Hydrochloride, chondroitin sulfate,
Collagen is raw material, and weight percent is respectively mountain Zhu's extract：3~40%；CNNS's Marasmius extract 5~30%,
D-Glucosamine Hydrochloride 5~40%, chondroitin sulfate 0.1~10%, collagen 1~15%.
106135890 A of patent document CN disclose a kind of suitable bone and the alimentation composition of patients with joint diseases,
It is by 20~40% ocean fish oligopeptides, 10~30% bone collagen peptides, 1~5% organic calcium, 1~5% casein phosphoric acid
Peptide, 0.1~1% Saussurea involucrata culture, 1~5% shark cartilage powder, 5~20% inulin, 5~30% oligosaccharide, 0.1~1% dimension life
The plurality of raw materials such as element, 1~3% minerals are made.
More than prior art only illustrates the effect of nutrition human body cartilaginous tissue, anti-inflammatory analgetic aspect, but cartilage is thin
Born of the same parents can not only synthesize the collagen and proteoglycans needed for cartilage, while can also generate the enzyme for decomposing aging collagen and proteoglycan.
The health-care food composition of the present invention is except nutrition cartilage, the anti-inflammatory effect of the prior art, also by clostridiopetidase A, elasticity
The apparent inhibitory action such as enzyme and hyaluronidase, and these enzymes are reduced to substances such as collagen, elastin laminin, hyaluronic acids
Destruction, simultaneously because OPCs effectively inhibits inflammatory factor such as PG, 5-HT and leukotrienes etc., and selectively and joint portion
Connective tissue combine to relieve pain and the symptoms such as oedema.
The content of the invention
According to an aspect of the present invention, it is an object of the present invention to provide a kind of health-care food composition, the guarantors
Health food composition can effectively prevent and treat articular cartilage damage, especially suitable caused by Articular cartilage degeneration
Arthralgia and joint function disturbance.
Health-care food composition according to the present invention includes following component：Bone collagen, II Collagen Type VI egg of hydrolysis
In vain, Caulis et Folium Brassicae capitatae, Pine Bark.Said composition inhibits chondroprotein point by increasing the colloid and mucus in joint
Enzyme is solved, slows down cartilage and is damaged, recombinate destroyed cartilage cell, new cartilaginous tissue and proteoglycan is promoted to synthesize, improves and closes
The generation of hyaluronic acid in section, formed a thickness it is real, effectively, with lubricating action neonychium, so as to reach anti-inflammatory, relieve pain
With the effect of oedema.
Specifically, the composition includes the ingredient of following parts by weight：200-1000 parts of bone collagen, II type glue of hydrolysis
50-650 parts of former protein 20 0-1500 parts, 50-600 parts of Caulis et Folium Brassicae capitatae and Pine Bark.
Preferably, the composition is composed of the following components in parts by weight：250-850 parts of bone collagen, II type of hydrolysis
300-1200 parts of collagen, 60-500 parts of Caulis et Folium Brassicae capitatae, 60-650 parts of Pine Bark.
Preferably, the composition is composed of the following components in parts by weight：300-850 parts of bone collagen, II type of hydrolysis
350-1000 parts of collagen, 100-350 parts of Caulis et Folium Brassicae capitatae, 300-650 parts of Pine Bark.
Not necessarily, the composition further includes 10-1000 parts of excipient, is preferably 50-800 parts.
The unit of above-mentioned parts by weight can be unit of weight well known to the medicine such as μ g, mg, g, kg and field of food.
The excipient is selected from starch, dextrin, talcum powder, cane sugar powder, ethyl alcohol, microcrystalline cellulose, lactose, hydroxypropyl
One or more of cellulose, sodium carboxymethylcellulose, magnesium stearate and superfine silica gel powder.These excipient are pharmaceutically may be used
The excipient of receiving.
In above-mentioned composition：
The hydrolysis typeⅡ Collagen is cleaned, enzymolysis, filtering, concentration, spray drying etc. using chicken cartilage as raw material
The content of product made of technique, wherein chondroitin sulfate accounts for dry weight generally not less than 20%；
The Caulis et Folium Brassicae capitatae is to eat part by fresh broccoli to extract after being dehydrated, dry, crush, then through ethyl alcohol
It forms, the content of wherein sulforaphen accounts for dry weight and is generally not less than 20mg/g；
The Pine Bark is using pine bark as raw material, is separated after ethyl alcohol extracts, procyanidins
(OPCs) content accounts for dry weight generally not less than 60%.
The dosage form of the composition includes：Tablet, pill, capsule, granule etc..
The conventional method that composition according to the present invention may be employed in the art is prepared, i.e., by weight
Proportioning weighs raw material, and bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark sieve, mixing,
It is spare；Then excipient is added in, clinically-acceptable any dosage form is made according to the conventional method of this field.
Advantageous effect：
Provided by the present invention for prevent and treat articular cartilage damage health-care food composition, by bone collagen,
Hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark are compounded in specific proportions, wherein, bone collagen
The colloid and mucus in joint can be increased, accelerate the reparation and existence of cartilaginous tissue and joint fluid；Hydrolysis typeⅡ Collagen contains
There are abundant hyaluronic acid and chondroitin sulfate, help against chondroprotein catabolic enzyme, recombinate destroyed cartilage cell, promote
Synthesized into new cartilaginous tissue and proteoglycan, improve the generation of intra-articular hyaluronic acid, formed a thickness it is real, effectively, carry
Lubricating action neonychium, protection is with lubricating joint connector and with powerful anti-inflammatory analgesic effect；In Caulis et Folium Brassicae capitatae
Sulforaphen causes the effect of a variety of enzymes of the degenerative joint of osteoarthritis by prevention, and process is damaged so as to slow down cartilage；Pine tree
The procyanidine enriched contained by bark extract has apparent inhibitory action to clostridiopetidase A, pancreatopeptidase E and hyaluronidase etc., so as to
Destruction of these enzymes to substances such as collagen, elastin laminin, hyaluronic acids is reduced, simultaneously because OPCs effectively inhibits to send out
The scorching factor such as PG, 5-HT and leukotrienes etc., and selectively combined to relieve pain with the connective tissue of joint portion with oedema etc.
Symptom.
Specific embodiment
Hereinafter, it will be described in detail the present invention.Before doing so, it should be appreciated that in this specification and appended
Claims in the term that uses should not be construed as being limited to general sense and dictionary meanings, and inventor should allowed
On the basis of appropriate definition term is to carry out the principle of best interpretations, according to meaning corresponding with the technical aspect of the present invention and generally
Thought explains.Therefore, description presented herein is not intended to limitation originally merely for the sake of the preferred embodiment for illustrating purpose
The scope of invention, it will thus be appreciated that without departing from the spirit and scope of the present invention, it can be obtained by it
His equivalents or improved procedure.
Following embodiment is enumerated only as the example of embodiment of the present invention, does not form any limit to the present invention
System, it will be appreciated by those skilled in the art that each falling within the present invention without departing from the modification in the range of the essence of the present invention and design
Protection domain.Unless stated otherwise, the reagent and instrument used in following embodiment is commercially available product.
Embodiment 1：
Choose raw material bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark mistake respectively
Sieve takes 40 mesh undersize materials to be used for preparing preparation.
The raw material screened is weighed respectively：Bone collagen 1000g, hydrolysis typeⅡ Collagen 250g, broccoli extraction
Object 300g, Pine Bark 60g, magnesium stearate 20g, stir, and pour into capsule filling mold, filling capsule,
3000 ball of capsule is made in polishing, packing.
Embodiment 2：
Choose raw material bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark mistake respectively
Sieve takes 80 mesh undersize materials to be used for preparing preparation.
The raw material screened is weighed respectively：Bone collagen 250g, hydrolysis typeⅡ Collagen 1500g, broccoli extraction
Object 60g, Pine Bark 650g, cane sugar powder 100g, stir, and concentration is the carboxymethyl of 0.8% (wt%)
Above-mentioned softwood is put into pill in pellet processing machine by the aqueous solution of sodium cellulosate as adhesive, softwood processed, drying, is dispensed after whole ball,
4000 balls are made.
Embodiment 3：
Choose raw material bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark mistake respectively
Sieve takes 80 mesh undersize materials to be used for preparing preparation.
The raw material screened is weighed respectively：Bone collagen 850g, hydrolysis typeⅡ Collagen 350g, Caulis et Folium Brassicae capitatae
500g, Pine Bark 450g, lactose 550g, microcrystalline cellulose 200g, stir, concentration 50%
(vol%) ethyl alcohol is made particle by the oscillating granulator of 14 mesh screens, particle is placed in more as adhesive, softwood processed
In function boiling drier, 50 DEG C of fluidized drying about 40min control pellet moisture as 3wt%-5wt%, whole grain, then
The magnesium stearate and superfine silica gel powder of raw material gross weight 0.5% are added in grain, total mixed, tabletting, film coating dispenses, and is made 3700
Piece.
Embodiment 4：
Choose raw material bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark mistake respectively
Sieve takes 80 mesh undersize materials to be used for preparing preparation.
The raw material screened is weighed respectively：Bone collagen 300g, hydrolysis typeⅡ Collagen 1200g, broccoli extraction
Object 80g, Pine Bark 300g, cane sugar powder 600g, stir, and the ethyl alcohol that concentration is 50% (vol%) is made
For adhesive, softwood processed is made particle by the oscillating granulator of 14 mesh screens, particle is placed in multi-functional boiling drier
In, 50 DEG C of fluidized drying about 40min control pellet moisture as 3wt%-5wt%, then whole grain, and granule 600 is made in packing
Bag.
Embodiment 5：
Except raw material composition is：Bone collagen 550g, hydrolysis typeⅡ Collagen 1000g, Caulis et Folium Brassicae capitatae 350g,
Beyond Pine Bark 180g, lactose 570g, magnesium stearate 20g, it is made according to the essentially identical preparation method of embodiment 3
3300.
EXPERIMENTAL EXAMPLE
1. experimental subjects and method
1.1 experimental subjects
This experiment whole subjects are knee joint damage soft tissue crowd, and male is 23 in 42 subjects, women
For 19, the age between 18-55, average age (37.3 ± 5.8) year.
1.2 experimental method
Grouping：42 subjects are randomly divided into 3 groups, control group (N=14), experimental group A (N=14), experimental group B (N=
14).Control group takes placebo, and 3 tablet per days are continuously taken 8 weeks；Experimental group A takes the composition tablet (embodiment of the present invention
3), 3 tablet per day is continuously taken 8 weeks；Experimental group B takes the composition tablet (embodiment 5) of the present invention, and 3 tablet per days continuously take 8
Week.Entire during the experiment, subject are not used, and including external application or take orally other drugs or food for helping to improve joint symptoms
Product.
1.3 main observation indexs：Dysfunction improves situation, using Lequesne index score standards.
1.3.1 knee joint rest pain
Normal is 0 point；Slightly, work is not influenced for 1 point；It is heavier, do not influence sleep for 2 points；Weight influences sleep for 3 points.
1.3.2 motion of knee joint pain
Normal is 0 point；It is 1 point that upper downstairs (slope), which has pain, bends and stretches without influence,；Upper downstairs (slope), squatting down has pain for 2
Point；Pain is 3 points during walking.
1.3.3 tenderness
Normal is 0 point；Pain is 1 point during weight；Moderate pressure pain is 2 points；Light pressure pain is 3 points.
1.3.4 swelling
Normal is 0 point；Slightly swollen, Xiyan is understood for 1 point；Soft tissue swelling, Xiyan are not clear as 2 points；Unclear Xiyan is 3
Point.
1.3.5 morning stiffness
Normal is 0 point；Bend and stretch it is stiff but quickly recover (<10min) it is 1 point；It is stiff, (10~30min) can be recovered in short-term
For 2 points；The stiff, long period just recover (>30min) it is 3 points.
1.3.6 locomotor activity
It is not limited to 0 point；Walking is more than 1km, but is limited and is made as 1 point；Walking about 1km or 15min is 2 points；Walking
500~900m or 8~15min is 3 points；300~500m of walking is 4 points；100~300m of walking is 5 points；Walking is less than 100m
6 points；Add 1 point using singly turning；Use crutches plus 2 points.
1.4 data statistics
The data obtained is examined using mono blind method and t and carries out statistical analysis to test data, used mean with Excel processing
± SD (mean+SD) represents that P ＞ 0.05 are considered as no significant difference, and P ＜ 0.05 are considered as significant difference, and P ＜ 0.01 are regarded
For pole significant difference.
2 experimental results and analysis
2.1 Lequesne index score results
Table 1 tests front and rear subject Lequesne index score results
* there is significant difference (p before and after taking<0.05)
As can be seen from Table 1, control group and experimental group A experiment after with test before compared with Lequesne index scores under
Drop, Lequesne index scores, which decline, before and after experimental group B experiments significant difference (p<0.05).
3. conclusion
It can be seen that bone collagen, hydrolysis typeⅡ Collagen, Caulis et Folium Brassicae capitatae, Pine Bark combine
The more common joint protection product function of product is stronger, and the product of composition of the present invention can especially be obviously improved pass
Save the dysfunction caused by cartilage damage.
Although above having used general explanation, specific embodiment and experiment, the present invention is made to retouch in detail
It states, but on the basis of the present invention, it can be made some modifications or improvements, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Scope.
Claims (7)
1. a kind of health-care food composition, the health-care food composition includes the ingredient of following parts by weight：Bone collagen
200-1000 parts, 200-1500 parts of typeⅡ Collagen of hydrolysis, 50-600 parts of Caulis et Folium Brassicae capitatae and Pine Bark 50-
650 parts.
2. health-care food composition according to claim 1, which is characterized in that the composition by following parts by weight into
It is grouped into：250-850 parts of bone collagen, 300-1200 parts of typeⅡ Collagen of hydrolysis, 60-500 parts of Caulis et Folium Brassicae capitatae, pine
60-650 parts of bark extract.
3. health-care food composition according to claim 1, which is characterized in that the composition by following parts by weight into
It is grouped into：300-850 parts of bone collagen, hydrolysis 350-1000 parts of typeⅡ Collagen, 100-350 parts of Caulis et Folium Brassicae capitatae,
300-650 parts of Pine Bark.
4. health-care food composition according to claim 1, which is characterized in that not necessarily, the composition further includes
10-1000 parts of excipient are preferably 50-800 parts.
5. health-care food composition according to claim 4, which is characterized in that the excipient be selected from starch, dextrin,
Talcum powder, cane sugar powder, ethyl alcohol, microcrystalline cellulose, lactose, hypromellose, sodium carboxymethylcellulose, magnesium stearate and micro-
One or more of powder silica gel.
6. health-care food composition according to claim 1, which is characterized in that in the composition：
The hydrolysis typeⅡ Collagen is the techniques such as cleaned, enzymolysis, filtering, concentration, spray drying using chicken cartilage as raw material
The content of manufactured product, wherein chondroitin sulfate accounts for dry weight generally not less than 20%；
The Caulis et Folium Brassicae capitatae be by fresh broccoli eat part after being dehydrated, dry, crushes, then through ethyl alcohol extract and
Into the content of wherein sulforaphen accounts for dry weight and is generally not less than 20mg/g；
The Pine Bark is using pine bark as raw material, is separated after ethyl alcohol extracts, procyanidins (OPCs)
Content account for dry weight generally not less than 60%.
7. health-care food composition according to claim 1, which is characterized in that the dosage form of the composition includes：Tablet,
Pill, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711365869.6A CN108112997B (en) | 2017-12-18 | 2017-12-18 | A health food composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711365869.6A CN108112997B (en) | 2017-12-18 | 2017-12-18 | A health food composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108112997A true CN108112997A (en) | 2018-06-05 |
| CN108112997B CN108112997B (en) | 2021-02-26 |
Family
ID=62229366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711365869.6A Active CN108112997B (en) | 2017-12-18 | 2017-12-18 | A health food composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108112997B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108968077A (en) * | 2018-07-13 | 2018-12-11 | 杭州相生相成科技有限公司 | A kind of elastin laminin Gly-His-Lys and preparation method thereof |
| CN111467481A (en) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | Composition for improving and/or preventing osteoarthritis and application thereof |
| CN111820348A (en) * | 2020-06-02 | 2020-10-27 | 大连普瑞康生物技术有限公司 | Saussurea involucrata culture ossein peptide composite fruit juice and preparation method thereof |
| CN116784480A (en) * | 2023-06-07 | 2023-09-22 | 北京康比特体育科技股份有限公司 | Composition containing hydrolyzed collagen II and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
| US20030091652A1 (en) * | 2001-11-13 | 2003-05-15 | Suhail Ishaq | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
| JP2003325136A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Arthritis-improving food |
| US20040086581A1 (en) * | 2002-11-06 | 2004-05-06 | Jones Edwin B. | Bio-energetic joint and arthritis pain formula |
| TW200744577A (en) * | 2005-07-13 | 2007-12-16 | Horphag Res Luxembourg Holding Sa | Method for treating osteoarthritis |
| CN101983722A (en) * | 2010-10-20 | 2011-03-09 | 北京康比特体育科技股份有限公司 | Composition for preventing and treating joint soft tissue injury and complications thereof |
| CN105725190A (en) * | 2016-02-15 | 2016-07-06 | 北京东方兴企食品工业技术有限公司 | Functional nutrient food for improving joints |
-
2017
- 2017-12-18 CN CN201711365869.6A patent/CN108112997B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
| US20030091652A1 (en) * | 2001-11-13 | 2003-05-15 | Suhail Ishaq | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
| JP2003325136A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Arthritis-improving food |
| US20040086581A1 (en) * | 2002-11-06 | 2004-05-06 | Jones Edwin B. | Bio-energetic joint and arthritis pain formula |
| TW200744577A (en) * | 2005-07-13 | 2007-12-16 | Horphag Res Luxembourg Holding Sa | Method for treating osteoarthritis |
| CN101983722A (en) * | 2010-10-20 | 2011-03-09 | 北京康比特体育科技股份有限公司 | Composition for preventing and treating joint soft tissue injury and complications thereof |
| CN105725190A (en) * | 2016-02-15 | 2016-07-06 | 北京东方兴企食品工业技术有限公司 | Functional nutrient food for improving joints |
Non-Patent Citations (1)
| Title |
|---|
| 佚名: "吃西兰花或有助预防关节炎 ", 《蔬菜》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108968077A (en) * | 2018-07-13 | 2018-12-11 | 杭州相生相成科技有限公司 | A kind of elastin laminin Gly-His-Lys and preparation method thereof |
| CN111467481A (en) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | Composition for improving and/or preventing osteoarthritis and application thereof |
| CN111820348A (en) * | 2020-06-02 | 2020-10-27 | 大连普瑞康生物技术有限公司 | Saussurea involucrata culture ossein peptide composite fruit juice and preparation method thereof |
| CN116784480A (en) * | 2023-06-07 | 2023-09-22 | 北京康比特体育科技股份有限公司 | Composition containing hydrolyzed collagen II and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108112997B (en) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103082276B (en) | Composition for reducing sport injury and promoting sport injury repair | |
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| CN108112997A (en) | A kind of health-care food composition | |
| CN101983722B (en) | Composition for preventing and treating joint soft tissue injury and complications thereof | |
| ES2682940T3 (en) | Composition comprising ocra for use in reducing the absorption of food fat | |
| CN102423487B (en) | Osteoarticular health-care composition and its application | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN104758360B (en) | It is a kind of to increase the composition of bone density | |
| CN105030879A (en) | Chitosan oligosaccharide bone-strengthening health product and preparation method thereof | |
| CN109480213A (en) | A kind of sport nutrition matched combined object with joint maintenance and maintenance | |
| CN104382005A (en) | Glucosamine chondroitin collagen tablet and preparation method thereof | |
| CN107349333B (en) | Composition with effect of increasing bone mineral density and preparation method and application thereof | |
| CN104605226A (en) | Healthcare product with function of increasing bone mineral density | |
| CN106262809A (en) | A kind of bone density that strengthens alleviates the compositions of person in middle and old age's arthralgia | |
| CN103656626B (en) | Compound complexing calcium preparation for treating and nourishing bones for middle and old aged people and preparation method thereof | |
| CN107616507A (en) | A kind of ocean polypeptide spy's dietary seafood for chornic arthritis edible for patients | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN101455396A (en) | Nutrient health-care food capable of promoting bone and bone arthrosis health | |
| CN104096221A (en) | Natural drug composition for curing rheumatism bone diseases and preparation method thereof | |
| CN110946994A (en) | Composition for increasing bone mineral density and preparation method thereof | |
| CN101171026A (en) | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| CN110897159A (en) | A composition for preventing or treating joint diseases | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| WO2021042275A1 (en) | Traditional chinese medicine composition for treating osteoarthritis | |
| CN106177908A (en) | A kind of have compositions increasing bone substance density improving function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |